A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)

Carboplatin and Gemcitabine Combination in Metastatic Triple-Negative Anthracycline- and Taxane-Pretreated Breast Cancer Patients: A Phase II Study

(2014) R. Maisano et al.   JOURNAL OF CHEMOTHERAPY

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

(2013) Lucia Del Mastro et al.   BMC CANCER

Molecularly targeted therapies for metastatic triple-negative breast cancer

(2013) Soley Bayraktar et al.   BREAST CANCER RESEARCH AND TREATMENT

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer

(2013) Jacques Medioni et al.   Drugs in research & development

Adjuvant treatments for triple-negative breast cancers

(2012) H. Joensuu et al.   ANNALS OF ONCOLOGY

Neoadjuvant treatments for triple-negative breast cancer (TNBC)

(2012) G. von Minckwitz et al.   ANNALS OF ONCOLOGY

Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?

(2011) J. T. Ribeiro et al.   ANNALS OF ONCOLOGY

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

(2011) J. M. Lohr et al.   ANNALS OF ONCOLOGY

Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis

(2011) U. Fasol et al.   ANNALS OF ONCOLOGY

Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype

(2011) Aoife J. Lowery et al.   BREAST CANCER RESEARCH AND TREATMENT

Cisplatin–gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients

(2010) Nebu Koshy et al.   BREAST

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

(2010) Christopher Lobo et al.   BREAST CANCER RESEARCH AND TREATMENT

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

(2010) Edith A. Perez et al.   BREAST CANCER RESEARCH AND TREATMENT

The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

(2010) Kenjiro Aogi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes

(2010) Amr S. Abu Lila et al.   PHARMACEUTICAL RESEARCH

Vascular targeting by EndoTAG™-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer

(2009) Martin E. Eichhorn et al.   INTERNATIONAL JOURNAL OF CANCER

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

(2009) Philippe L. Bedard et al.   Nature Reviews Clinical Oncology

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

(2008) Martine J. Piccart-Gebhart et al.   JOURNAL OF CLINICAL ONCOLOGY